Abstract 422P
Background
Metastatic osteosarcoma at presentation forms 10 to 20% of total osteosarcomas diagnosed. They have a very poor prognosis compared to non-metastatic subset. Patients with resectable metastasis have a better DFS and OS compared to unresectable metastatic disease at presentation. This study was done to find the response rate to first line cisplatin and adriamycin combination chemotherapy to upfront metastatic osteosarcoma patients and time to progression after first line chemotherapy. Secondary objective was to find the overall survival.
Methods
Patients diagnosed with osteosarcoma at madras medical college were identified from the database for a period of 5.5 years from January 2013 to June 2018. From that patients who had metastasis at presentation were further sorted out and taken for analysis.
Results
77 patients were diagnosed to have osteosarcoma during the 5.5year period. Among them 36 patients had metastatic disease at presentation. 28 patients were male (77.8%) and 8 patients were female (22.2%). Median age of the patients was 19.5 years. 23 patients had ECOG PS 2 (63.9%) and 12 had ECOG PS 1 (33.3%) and 1 had ECOG PS 3 (2.8%). Tibia and femur were the most common primary site (75%). 5 patients had resectable lung metastasis and underwent pulmonary metastasectomy and were excluded from analysis and 1 patient was on palliative care only. Among remaining 30 patients, 27 patients had multiple lung metastasis (90%) and 3 patients had bone metastasis (10%). 30 patients received 6 cycles of chemotherapy with adriamycin 25mg/m2 on d1-d3 and cisplatin 100mg/m2 on d1 repeated every 21 days except 3 who progressed during chemotherapy. 17 patients (56.7%) had grade 1-2 vomiting. No one developed any acute cardiotoxicity. No treatment related death occurred. At the end of 6 cycles, 22 patients (73.3%) had partial response and 5 patients (16.7%) had stable disease and 3 patients (10%) had progressive disease. Median time to progression was 11.5 months. 2year OS was 73.3%.
Conclusions
This platinum doublet is a reasonable option for these patients as most of them are young.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sivasubramaniam Kumaravelu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session
105P - Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
Presenter: Tsai-Sheng Yang
Session: e-Poster Display Session
106P - Efficacy and tolerability of capecitabine and mitomycin-C based concurrent radiotherapy in patients with anal canal cancer
Presenter: Prabhat Bhargava
Session: e-Poster Display Session
107P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
Presenter: Timothy Price
Session: e-Poster Display Session
108P - Comparative analysis of two-stage hepatectomy and enhanced one-stage hepatectomy in the setting of bilobar colorectal liver metastases
Presenter: Hayk Torgomyan
Session: e-Poster Display Session
109P - Efficacy and safety of biweekly or triweekly XELOX regimen for adjuvant chemotherapy of colorectal cancer
Presenter: hangyu zhang
Session: e-Poster Display Session
110P - Analysis for stereotactic body radiotherapy (SBRT) effect for colorectal liver metastases
Presenter: Wei Zou
Session: e-Poster Display Session
111P - A meta-analysis study on safety and effectiveness comparison between FOLFOX and XELOX regiments on advanced stage colorectal cancer
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
112P - Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study
Presenter: Takayuki Yoshino
Session: e-Poster Display Session
122P - Nomogram to predict short-term effect of radiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma
Presenter: Shuai Liang
Session: e-Poster Display Session